tracken
Eli Lilly and Company Aktie News
Positiv
Reuters
●
etwa 12 Stunden alt
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain patients with early Alzheimer's disease, reversing an initial decision from four months ago.
Neutral
PRNewsWire
●
etwa 13 Stunden alt
INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Neutral
PRNewsWire
●
etwa 16 Stunden alt
The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending donanemab for the treatment of early symptomatic Alzheimer...
Neutral
Business Wire
●
ein Tag alt
BRISBANE, Calif.--(BUSINESS WIRE)--Insert updated third paragraph, first sentence of release: Under the terms of the agreement, Gate will receive an upfront payment and equity investment and will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales, with a total deal value up to ...
Positiv
Barrons
●
ein Tag alt
Morgan Stanley strategists highlighted companies that look likely to report strong numbers, including Chewy, Eaton, Nvidia, and Eli Lilly.
Positiv
The Motley Fool
●
ein Tag alt
Eli Lilly (LLY 0.15%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong clinical and regulatory progress, as well as robust financial results, the drugmaker has routinely impressed Wall Street.
Neutral
PRNewsWire
●
ein Tag alt
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Negativ
Barrons
●
ein Tag alt
Viking Therapeutics is expected to disclose data on its oral weight-loss drug VK2735.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
